Just weeks before a big conference in Las Vegas, new real-world data confirmed that EKOS, an embolization product from Boston Scientific, was safer than their leading competitor. This was good news under regular circumstances. Great news given the competitor was traipsing around town claiming superiority. We created a campaign that put BSC on the offensive.